Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
Alexander Peikert, Parag Goyal, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Zi Michael Miao, Orly Vardeny, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
Topics & Concepts
MedicineEjection fractionPolypharmacyDapagliflozinHeart failureCardiologyInternal medicineIntensive care medicineDiabetes mellitusEndocrinologyType 2 diabetesDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management